Navigation Links
Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital
Date:5/15/2009

LA JOLLA, Calif., May 15 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights jointly owned by Children's Hospital Boston and Massachusetts General Hospital. This intellectual property covers compositions and methods for supporting hematopoietic stem cells. These proprietary technologies developed by Leonard Zon, M.D., director of the Stem Cell Program at Children's Hospital Boston and a scientific founder of Fate Therapeutics, expand the Company's broad intellectual property portfolio for modulating the activity and state of stem cells. Fate Therapeutics is utilizing its adult stem cell biology engine and induced pluripotent stem (iPS) cell technology platform to develop Stem Cell Modulators (SCMs) - small molecules and biologics that guide cell fate for therapeutic purposes.

"Over the past two years, Fate Therapeutics has amassed extensive intellectual property assets as a foundation for our adult stem cell biology engine," said Paul Grayson, president and CEO of Fate Therapeutics. "The agreement we signed today with Children's Hospital and the technologies associated with it continue to expand our engine and accelerate the Company's core mission to develop small molecules and biologics that modulate adult stem cells for regenerative medicine."

The exclusive rights acquired today will be incorporated into Fate Therapeutics' growing adult stem cell biology engine, which also includes exclusive rights to the pioneering work of the Company's scientific founders and other leaders in the field. Adult stem cells are naturally-occurring cells found in almost all tissues or organs in the body and are primarily responsible for maintaining and repairing their native tissue. An adult stem cell has unique properties
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... have observed the "hot electron" effect in a solar ... elusive charges using ultra-thin solar cells, opening a potential ... in the current online edition of Applied Physics ... cells, it generates free electrons in a range of ... the electrons must reach the bottom of the conduction ...
(Date:12/11/2009)... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... appointment of Dr. Alan Warrander to the role ... Development. ,, "Dr. Warrander will be responsible for ... REOLYSIN(R)," said Dr. Brad Thompson, President and CEO ... design of a Phase 3 trial examining REOLYSIN ...
(Date:12/10/2009)... the National Institutes of Health (NIH), awarded a $2.18 million ... a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. ... ... UT (PRWEB) December 10, 2009 -- The National Eye Institute ... awarded a $2.18 million grant to Aciont Inc. to help ...
(Date:12/10/2009)... China Biologic,Products, Inc. (Nasdaq: CBPO ) ("China ... biopharmaceutical companies in China, today announced,that the Company,s ... at the,NASDAQ MarketSite in New York City at ... China Biologic,s common stock ... 2, 2009, under the ticker symbol "CBPO." , ...
Breaking Biology Technology:Elusive 'hot' electrons captured in ultra-thin solar cells 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3China Biologic Products to Ring NASDAQ Opening Bell 2China Biologic Products to Ring NASDAQ Opening Bell 3
... 1 April was Wall Street,s best month in nine ... the economy is about to begin a turnaround. The Dow ... in April, on top of a 7.7 percent gain in ... as investors were not phased by a World Health Organization ...
... Increase of 29% over First Quarter 2008- Earnings Per Share ... Increases of 14% and 20% over First Quarter 2008, respectively ... UTHR ) today announced its results of operations ... for the first quarter of 2009 were $79.7 million, up ...
... and Student Research, Partnering with Industry , ... ... University of Massachusetts Boston today officially opened a cutting-edge ... university,s research and development activity and provide entrepreneurial opportunities for ...
Other Biology Technology:Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll 2Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll 3United Therapeutics Reports First Quarter 2009 Financial Results 2United Therapeutics Reports First Quarter 2009 Financial Results 3United Therapeutics Reports First Quarter 2009 Financial Results 4United Therapeutics Reports First Quarter 2009 Financial Results 5United Therapeutics Reports First Quarter 2009 Financial Results 6United Therapeutics Reports First Quarter 2009 Financial Results 7UMass Boston Opens Venture Development Center to Expand R&D Activity 2UMass Boston Opens Venture Development Center to Expand R&D Activity 3UMass Boston Opens Venture Development Center to Expand R&D Activity 4
(Date:12/13/2009)... five genetic variants that are associated with the health ... consortium of 96 scientists from 63 centres in Europe ... of lung diseases. , The new findings provide hope ... Pulmonary Disease (COPD) and asthma. In the past it ... molecular pathways that affect the health of the lung ...
(Date:12/11/2009)... BATON ROUGE, LAKeeping with the global "green" ... environmental education lessons to enhance students, science ... education into the curriculum raises not just ... test scores in other subject areas. Naturally, ... to integrate these relevant lessons into the ...
(Date:12/11/2009)... wild apples that could be an ancestor of today,s ... Asia. A new study comparing the diversity of recently ... Armenia with previously collected varieties originating in Russia and ... collection that will make M. orientalis more ... identify and record the genetic diversity of these wild ...
Breaking Biology News(10 mins):New genes for lung disease discovered 2Students learn environmental stewardship, improve science scores 2Understanding apples' ancestors 2Tianyin Pharmaceutical Co to Present at the Rodman 26 Renshaw Annual Global Investment Conference on September 11 at 10 3A50 am ET 13735 1Tianyin Pharmaceutical Co to Present at the Rodman 26 Renshaw Annual Global Investment Conference on September 11 at 10 3A50 am ET 13735 2Tianyin Pharmaceutical Co to Present at the Rodman 26 Renshaw Annual Global Investment Conference on September 11 at 10 3A50 am ET 13735 3HOYA ConBio Announces Educational Alliance with LVI Global Australia 55683 1HOYA ConBio Announces Educational Alliance with LVI Global Australia 55683 2Sundia Receives the Highest Growth Potential Award from Zhangjiang 55681 1Sundia Receives the Highest Growth Potential Award from Zhangjiang 55681 2
... the genetics of barley could lead to improved varieties ... of whisky and beer. Scientists funded in part by ... beginning a new programme to uncover key genes that ... The research, being carried out at the Scottish Crop ...
... game between pathogens and the hosts they infect, researchers have ... recently discovered gene silencing device to evade detection and destruction ... Institute (HHMI) researchers in an article published in the June ... show how a virus uses the gene silencing machinery for ...
... the Sinclair gasoline logo and Fred Flintstone's gravel pit tractor---are ... look alike. , The largest animals known to have ... the middle of the dinosaur era but were thought to ... the end of that era. New discoveries, however, are showing ...
Other Biology News:Whisky fans can drink to crop research 2Virus uses tiny RNA to evade the immune system 2Virus uses tiny RNA to evade the immune system 3Skull study sheds light on dinosaur diversity 2Skull study sheds light on dinosaur diversity 3
...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
... The pAcAB4 vector is a 10.0 kb ... contains two,copies of the AcNPV polyhedrin promoter ... the first p10,promoter is a Sma I ... sequences. Upstream of this,an inverted polyhedrin promoter ...
Biology Products: